229 related articles for article (PubMed ID: 12602521)
1. Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy.
Kircheis G; Wettstein M; Dahl Sv; Häussinger D
Metab Brain Dis; 2002 Dec; 17(4):453-62. PubMed ID: 12602521
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
[TBL] [Abstract][Full Text] [Related]
3. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.
Stauch S; Kircheis G; Adler G; Beckh K; Ditschuneit H; Görtelmeyer R; Hendricks R; Heuser A; Karoff C; Malfertheiner P; Mayer D; Rösch W; Steffens J
J Hepatol; 1998 May; 28(5):856-64. PubMed ID: 9625322
[TBL] [Abstract][Full Text] [Related]
4. Current state of knowledge of hepatic encephalopathy (Part V): clinical efficacy of L-ornithine-L-aspartate in the management of HE.
Kircheis G
Metab Brain Dis; 2016 Dec; 31(6):1365-1367. PubMed ID: 27838865
[TBL] [Abstract][Full Text] [Related]
5. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
Ahmad I; Khan AA; Alam A; Dilshad A; Butt AK; Shafqat F; Malik K; Sarwar S
J Coll Physicians Surg Pak; 2008 Nov; 18(11):684-7. PubMed ID: 18983791
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
Blanco Vela CI; Poo Ramírez JL
Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.
Poo JL; Góngora J; Sánchez-Avila F; Aguilar-Castillo S; García-Ramos G; Fernández-Zertuche M; Rodríguez-Fragoso L; Uribe M
Ann Hepatol; 2006; 5(4):281-8. PubMed ID: 17151582
[TBL] [Abstract][Full Text] [Related]
8. [Prevention and treatment of hepatic encephalopathy].
Sivolap YP
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy].
Chen MF; Li RC; Chen CH; Gao XC
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):718-9, 722. PubMed ID: 15958319
[TBL] [Abstract][Full Text] [Related]
10. A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment.
Soárez PC; Oliveira AC; Padovan J; Parise ER; Ferraz MB
Arq Gastroenterol; 2009; 46(3):241-7. PubMed ID: 19918694
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
Schmid M; Peck-Radosavljevic M; König F; Mittermaier C; Gangl A; Ferenci P
Liver Int; 2010 Apr; 30(4):574-82. PubMed ID: 20456040
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.
Mittal VV; Sharma BC; Sharma P; Sarin SK
Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):725-32. PubMed ID: 21646910
[TBL] [Abstract][Full Text] [Related]
13. [The treatment of hepatic encephalopathy with Hepa-Mertz].
Podymova SD; Bueverov AO; Nadinskaia MIu
Ter Arkh; 1995; 67(6):45-7. PubMed ID: 7667779
[TBL] [Abstract][Full Text] [Related]
14. The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition.
Ndraha S; Hasan I; Simadibrata M
Acta Med Indones; 2011 Jan; 43(1):18-22. PubMed ID: 21339541
[TBL] [Abstract][Full Text] [Related]
15. Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study.
Ong JP; Oehler G; Krüger-Jansen C; Lambert-Baumann J; Younossi ZM
Clin Drug Investig; 2011; 31(4):213-20. PubMed ID: 21208014
[TBL] [Abstract][Full Text] [Related]
16. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
Bai M; Yang Z; Qi X; Fan D; Han G
J Gastroenterol Hepatol; 2013 May; 28(5):783-92. PubMed ID: 23425108
[TBL] [Abstract][Full Text] [Related]
17. L-ornithine vs. L-ornithine-L-aspartate as a treatment for hyperammonemia-induced encephalopathy in rats.
Vogels BA; Karlsen OT; Mass MA; Boveé WM; Chamuleau RA
J Hepatol; 1997 Jan; 26(1):174-82. PubMed ID: 9148009
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials.
He Q; Mao C; Chen Z; Zeng Y; Deng Y; Hu R
Arab J Gastroenterol; 2024 May; 25(2):84-92. PubMed ID: 38403493
[TBL] [Abstract][Full Text] [Related]
19. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
Butterworth RF; McPhail MJW
Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425
[TBL] [Abstract][Full Text] [Related]
20. Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine.
Garrido M; Skorucak J; Raduazzo D; Turco M; Spinelli G; Angeli P; Amodio P; Achermann P; Montagnese S
Metab Brain Dis; 2016 Aug; 31(4):965-74. PubMed ID: 27193025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
